13 new sobering stations at MultCo defelction center provide ‘path to recovery'
On Wednesday, county officials announced that 24-hour beds would come online as part of a phased plan to eventually open a separate Sobering & Crisis Stabilization Center at 1901 SE Grand Ave.
While the permanent sobering center, with up to 50 withdrawal management stations is slated to open in the Fall of 2027, county leaders said the current expansion will help increase access to recovery services for people suffering from substance abuse disorder.
Commissioner Julia Brim-Edwards, who led the sobering center plan, said the expansion would offer law enforcement more opportunities to refer people caught with illegal drugs to treatment instead of jail, including those experiencing acute intoxication.
'The community and first responders have been clear about the need for sobering as an alternative to emergency departments, jail, or leaving people on the streets,' said Brim-Edwards. 'By offering a safe and supportive environment, we can help individuals begin their journey to recovery, while improving community safety and reducing the burdens on our emergency medical and justice systems.'
The announcement comes after the Coordinated Care Pathway Center switched to a 24-hour model on April 14.
Previously, law enforcement could only refer qualifying drug offenders to the Coordinated Care Pathway Center for deflection on weekdays from 7 a.m. to 11 p.m. and weekends from 7 a.m. to 3 p.m.
'These 13 sobering beds expand our capacity to provide a safe, stable place to go for people needing care and respite on their path to recovery,' said Chair Jessica Vega Pederson. 'This new 24/7 resource fills a critical gap in crisis services that will benefit law enforcement partners, first responders, and our broader community. It's an important addition to our larger continuum of care.'
The Portland Metro region has seen a gap in low-barrier drop-off locations since 2019, when the city closed its sobering center.
Following construction delays, the Coordinated Care Pathway Center opened on October 14, 2024, shortly after the implementation of House Bill 4002.
The law re-introduced criminal penalties for people possessing small amounts of hard drugs in Oregon and granted counties the ability to build deflection programs to help people with addiction.
According to county data, between September 1, 2024, when Multnomah County kicked off its deflection program and February 28, 2025, law enforcement referred 267 people to participate in deflection.
The county claims the center's service provider Tuerk House will prioritize referrals for sobering stations from law enforcement deflection before offering availability to outreach workers, first responders, and other service groups.
'We are committed to providing patient-centered, trauma-informed care,' said Bernard Gyebi-Foster, Chief Executive Officer of Tuerk House. 'Our services are designed to offer a pathway to treatment and support, addressing the complex needs of each individual. With the opening of 24/7 sobering services, we are now able to provide immediate treatment around the clock to those in need, and we have a longer time to make a more meaningful connection with them. While they are with us, our goal will be to get to know each person as best as we can and help them make informed decisions about the best next step in their recovery.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
06-08-2025
- Yahoo
FTC moves to block Edwards' JenaValve acquisition
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. The Federal Trade Commission has moved to block Edwards Lifesciences' planned acquisition of JenaValve Technology, citing concerns that the deal threatens to reduce competition in the market for devices to treat aortic regurgitation. The agency alleged that over two days in July 2024, Edwards signed agreements to acquire both JenaValve and JC Medical, the two leading companies competing to bring transcatheter aortic valve replacement devices to market to treat the potentially fatal heart condition. Edwards closed the acquisition of JC Medical in August 2024. The FTC said Edwards' proposed $945 million acquisition of JenaValve would combine the only two companies conducting U.S. clinical trials for a TAVR aortic regurgitation, or TAVR-AR, device. 'The deal threatens to reduce competition in the TAVR-AR market, likely resulting in reduced innovation, diminished product quality, and potentially increased prices for consumers,' the agency stated in a federal court complaint. The commission voted 3-0 to issue an administrative complaint and seek a temporary restraining order and a preliminary injunction to halt the transaction pending an administrative proceeding. The complaint and injunction request were filed in the U.S. District Court for the District of Columbia. JenaValve is poised to become the first company to bring a TAVR-AR device, called Trilogy, to the U.S. market, the FTC said. Food and Drug Administration approval of a TAVR-AR device by another company besides Edwards and JenaValve is not expected in the foreseeable future. 'The FTC is taking action to stop this anticompetitive deal and ensure that JenaValve and Edwards' JC Medical subsidiary continue competing to innovate, expand treatment eligibility, and keep down costs,' Daniel Guarnera, director of the FTC's Bureau of Competition, said in the agency's Wednesday statement. Edwards' stance Edwards said Wednesday that it disagrees with the FTC's decision and believes it will limit the treatment options for patients with aortic regurgitation. Edwards argued that the acquisition will actually 'accelerate the availability, adoption and continued innovation of a life-saving treatment for patients suffering from AR.' The company plans to continue to pursue regulatory approval for the deal and expects a final determination by the end of the first quarter of 2026. JenaValve also said that it remains committed to completing the transaction and is confident in the rationale for the merger and the value it will bring to patients. The company intends to join Edwards to defend the case in court. Edwards increased its forecast for 2025 adjusted earnings per share to the high end of a range of $2.45 to $2.55, up from the high end of a range of $2.40 to $2.50, to reflect the impact of the FTC's action. The company said there is no impact to revenue guidance. Edwards agreed to pay $1.2 billion combined in July 2024 to buy JenaValve and Endotronix, which makes an implantable heart failure sensor. With the Endotronix transaction completed, Edwards was expecting the JenaValve deal to close in the middle of this year. Recommended Reading Edwards shrugs off tariffs, backs 2025 profit forecast
Business Wire
06-08-2025
- Business Wire
Edwards Lifesciences Comments on FTC's Action to Block Proposed Acquisition of JenaValve
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition of JenaValve Technology. Edwards disagrees with FTC's decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation (AR). The company further believes the acquisition of JenaValve will accelerate the availability, adoption and continued innovation of a life-saving treatment for patients suffering from AR. AR is a deadly and progressive disease that affects a significant and growing number of patients, many of whom currently have limited treatment options. Edwards intends to continue to pursue regulatory approval of the acquisition and estimates a final determination by the end of Q1 2026. In light of FTC's action, Edwards is revising its full-year 2025 financial guidance. There is no impact to revenue guidance. The company is increasing its adjusted 1 Earnings Per Share (EPS) guidance for the full year to the high-end of $2.45-$2.55, up from the high-end of $2.40-$2.50. There will be minimal impact to the company's Q3 adjusted EPS guidance. [1] Adjusted earnings per share is a non-GAAP item computed on a diluted basis and in this release also excludes certain litigation expenses, amortization of intangible assets, loss on impairment and separation costs. See 'Non-GAAP Financial Information' in this release. Diluted earnings per share are from continuing operations. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at and follow us on LinkedIn, Facebook, Instagram and YouTube. This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statements contained in this release to be covered by the safe harbor provisions of such Acts. These forward-looking statements can sometimes be identified by the use of forward-looking words, such as 'may,' 'might,' 'believe,' 'will,' 'expect,' 'project,' 'estimate,' 'should,' 'anticipate,' 'plan,' 'goal,' 'continue,' 'seek,' 'intend,' 'optimistic,' 'aspire,' 'confident' and other forms of these words and include, but are not limited to, statements regarding the continued pursuit of regulatory approval, a final determination of the transaction by the end of the first quarter of 2026, impact on patient lives and the company's revised financial guidance and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Non-GAAP Financial Information Projections for diluted earnings per share from continuing operations are provided on a non-GAAP basis as adjusted to exclude certain litigation expenses, amortization of intangible assets, loss on impairment, and separation costs. The company is not able to provide a reconciliation of the non-GAAP guidance to comparable GAAP measures due to the unknown effect, timing, and potential significance of special charges or gains, and management's inability to forecast charges associated with future transactions and initiatives. Edwards, Edwards Lifesciences, and the stylized E logo, are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
Yahoo
06-08-2025
- Yahoo
Clackamas County resident exposed to bat with rabies
PORTLAND, Ore. (KOIN) – A person is receiving treatment after being exposed to a bat with rabies inside their Molalla home, Clackamas County officials said Tuesday. The exposure happened inside a private residence and testing began on Aug. 1. The bat was euthanized, and tests confirmed the bat had rabies, health officials said. Rare 360-degree photos of Oregon life in 1900s now online Public health officials say bats are the main source of rabies exposures in Oregon, with approximately 8% of the tested population carrying the virus — though officials say the true number could be lower in the wild.. According to Clackamas County officials, exposures are more common in the summer. 'In the last five years, Clackamas County has averaged one bat per year that has tested positive for rabies,' said Clackamas County Health Officer Dr. Sarah Present. However, Present said exposure to rabies can be avoided. 'Rabies is a deadly illness that can be prevented with treatment immediately after someone is exposed,' she said. 'But we would rather prevent exposures in the first place, and you can do that by taking simple precautions to protect yourself, your family and your pets.' 'Heightened level of callousness': Woodburn man sentenced for robberies with fake bomb vest Officials recommend vaccinating your pets and feeding them indoors, using screens in open windows and doors, and sealing openings to attics, basements, porches, sheds, barns and chimneys. If you or anyone you know is exposed to a wild bat — alive or dead — call a professional wildlife removal service and avoid touching the animal. If you are scratched by one, immediately wash the area with soap and water for at least five minutes and seek medical help. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
